Clinical trial · Interventional
Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): change in imaging priorities
Summary
Brief summary (as posted)
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CNS Brain Metastases | — | UNRESOLVED | — |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET CuATSM | Procedure | — | UNRESOLVED |
| PET Imaging | Procedure | — | UNRESOLVED |
| PET-imaging with CuATSM | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- 1 CNS
- description
- imaging with CuATSM
- interventionNames
- Procedure: PET-imaging with CuATSM
- Procedure: PET Imaging
- type
- EXPERIMENTAL
- label
- 2. Head and Neck
- description
- Imaging with CuATSM
- interventionNames
- Procedure: PET CuATSM
- type
- EXPERIMENTAL
- label
- 3. Lung
- description
- imaging with CuATSM
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Able to tolerated a PET/CT scan * Age 18 or older * Patient being considered for XRT for treatment of their cancer * Able to provide written informed consent Exclusion Criteria: * severe claustrophobia or inability to tolerate the PET scan * pregnant or breastfeeding women * Patients that need supplemental oxygen * Patients enrolled in experimental treatments
References
Publications (0)
Data not yet available